Arcturus Therapeutics Holdings Inc (ARCT) - Net Assets
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has net assets worth $171.81 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($224.31 Million) and total liabilities ($52.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Arcturus Therapeutics Holdings Inc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $171.81 Million |
| % of Total Assets | 76.59% |
| Annual Growth Rate | 46.86% |
| 5-Year Change | -6.23% |
| 10-Year Change | 353.09% |
| Growth Volatility | 394.46 |
Arcturus Therapeutics Holdings Inc - Net Assets Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ARCT market cap overview.
Annual Net Assets for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual net assets of Arcturus Therapeutics Holdings Inc from 2011 to 2025. Also explore ARCT net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $213.99 Million | -11.20% |
| 2024-12-31 | $240.98 Million | -13.48% |
| 2023-12-31 | $278.51 Million | +3.03% |
| 2022-12-31 | $270.31 Million | +18.45% |
| 2021-12-31 | $228.21 Million | -42.45% |
| 2020-12-31 | $396.55 Million | +1437.50% |
| 2019-12-31 | $25.79 Million | +89.06% |
| 2018-12-31 | $13.64 Million | -59.63% |
| 2017-12-31 | $33.79 Million | -28.44% |
| 2016-12-31 | $47.23 Million | -31.88% |
| 2015-12-31 | $69.33 Million | +247.65% |
| 2014-12-31 | $19.94 Million | -59.04% |
| 2013-12-31 | $48.69 Million | +8686.95% |
| 2012-12-31 | $-567.00K | -157.56% |
| 2011-12-31 | $985.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcturus Therapeutics Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50798300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.01% |
| Other Components | $728.55 Million | 340.47% |
| Total Equity | $213.99 Million | 100.00% |
Arcturus Therapeutics Holdings Inc Competitors by Market Cap
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABG Sundal Collier Holding ASA
OL:ABG
|
$393.70 Million |
|
Zhuhai Kles Technology Co. Ltd. A
SHE:301314
|
$393.73 Million |
|
Lanpec Technologies Ltd
SHG:601798
|
$393.76 Million |
|
Sunfly Intelligent Technology Co Ltd
SHE:300423
|
$393.86 Million |
|
Bonree Data Technology Co Ltd
SHG:688229
|
$393.53 Million |
|
Shanghai Laimu Electronics Co Ltd
SHG:603633
|
$393.47 Million |
|
Ambac Financial Group Inc
NYSE:AMBC
|
$393.43 Million |
|
Shoe Carnival Inc
NASDAQ:SCVL
|
$393.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcturus Therapeutics Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,978,000 to 213,985,000, a change of -26,993,000 (-11.2%).
- Net loss of 65,783,000 reduced equity.
- New share issuances of 12,273,000 increased equity.
- Other factors increased equity by 26,517,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-65.78 Million | -30.74% |
| Share Issuances | $12.27 Million | +5.74% |
| Other Changes | $26.52 Million | +12.39% |
| Total Change | $- | -11.20% |
Book Value vs Market Value Analysis
This analysis compares Arcturus Therapeutics Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.35x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.62 | $13.85 | x |
| 2012-12-31 | $-0.36 | $13.85 | x |
| 2013-12-31 | $33.49 | $13.85 | x |
| 2014-12-31 | $10.21 | $13.85 | x |
| 2015-12-31 | $22.43 | $13.85 | x |
| 2016-12-31 | $11.99 | $13.85 | x |
| 2017-12-31 | $10.95 | $13.85 | x |
| 2018-12-31 | $1.35 | $13.85 | x |
| 2019-12-31 | $2.14 | $13.85 | x |
| 2020-12-31 | $19.53 | $13.85 | x |
| 2021-12-31 | $8.67 | $13.85 | x |
| 2022-12-31 | $9.98 | $13.85 | x |
| 2023-12-31 | $10.46 | $13.85 | x |
| 2024-12-31 | $8.93 | $13.85 | x |
| 2025-12-31 | $7.81 | $13.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcturus Therapeutics Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -97.86%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.27x
- Recent ROE (-30.74%) is above the historical average (-75.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -398.88% | 0.00% | 0.00x | 1.22x | $-4.03 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.52 Million |
| 2013 | -21.66% | 0.00% | 0.00x | 1.03x | $-15.42 Million |
| 2014 | -164.64% | 0.00% | 0.00x | 1.12x | $-34.83 Million |
| 2015 | -28.05% | -316.86% | 0.09x | 1.03x | $-26.38 Million |
| 2016 | -52.09% | -120.71% | 0.40x | 1.09x | $-29.33 Million |
| 2017 | -32.26% | -83.87% | 0.25x | 1.54x | $-14.28 Million |
| 2018 | -159.69% | -138.29% | 0.36x | 3.24x | $-23.15 Million |
| 2019 | -100.77% | -125.02% | 0.25x | 3.18x | $-28.57 Million |
| 2020 | -18.19% | -756.35% | 0.02x | 1.20x | $-111.80 Million |
| 2021 | -89.25% | -1647.98% | 0.03x | 1.72x | $-226.50 Million |
| 2022 | 3.46% | 4.54% | 0.46x | 1.67x | $-17.68 Million |
| 2023 | -10.67% | -18.84% | 0.37x | 1.54x | $-57.58 Million |
| 2024 | -33.59% | -58.49% | 0.40x | 1.43x | $-105.04 Million |
| 2025 | -30.74% | -97.86% | 0.25x | 1.27x | $-87.18 Million |
Industry Comparison
This section compares Arcturus Therapeutics Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $203,084,613
- Average return on equity (ROE) among peers: -26.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc (ARCT) | $171.81 Million | -398.88% | 0.31x | $393.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $110.17 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $308.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $30.56K | -78.85% | 1.11x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.95 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $30.68 Million | -84.47% | 0.32x | $3.56 Billion |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more